RT Journal Article
SR Electronic
T1 ACTIVATE-2: A DOUBLE-BLIND RANDOMIZED TRIAL OF BCG VACCINATION AGAINST COVID19 IN INDIVIDUALS AT RISK
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.20.21257520
DO 10.1101/2021.05.20.21257520
A1 Tsilika, Maria
A1 Taks, Esther
A1 Dolianitis, Konstantinos
A1 Kotsaki, Antigone
A1 Leventogiannis, Konstantinos
A1 Damoulari, Christina
A1 Kostoula, Maria
A1 Paneta, Maria
A1 Adamis, Georgios
A1 Papanikolaou, Ilias C.
A1 Stamatelopoulos, Kimon
A1 Bolanou, Amalia
A1 Katsaros, Konstantinos
A1 Delavinia, Christina
A1 Perdios, Ioannis
A1 Pandi, Aggeliki
A1 Tsiakos, Konstantinos
A1 Proios, Nektarios
A1 Kalogianni, Emmanouela
A1 Delis, Ioannis
A1 Skliros, Efstathios
A1 Akinosoglou, Karolina
A1 Perdikouli, Aggeliki
A1 Poulakou, Garyfallia
A1 Milionis, Haralampos
A1 Athanassopoulou, Eva
A1 Kalpaki, Eleftheria
A1 Efstratiou, Leda
A1 Perraki, Varvara
A1 Papadopoulos, Antonios
A1 Netea, Mihai G.
A1 Giamarellos-Bourboulis, Evangelos J.
YR 2021
UL http://medrxiv.org/content/early/2021/05/24/2021.05.20.21257520.abstract
AB BCG vaccination induces heterologous protection against respiratory tract infections, and in children improves survival independently of tuberculosis prevention. The phase III ACTIVATE-2 study assessed whether BCG could also protect against COVID19 in the elderly. In this double-blind, randomized trial, elderly Greek patients were randomized (1:1) to receive either BCG revaccination or placebo at hospital discharge, followed by 6 months observation for incidence of COVID19 infection. BCG revaccination resulted in 68% risk reduction for total COVID19 clinical and microbiological diagnoses (OR 0.32, 95% CI 0.13-0.79). Five patients in the placebo group and one in the BCG-vaccinated group had severe COVID19 that necessitated hospitalization. 3 months after BCG vaccination 1.3% of placebo and 4.7% of BCG-vaccinated volunteers had anti-SARS-CoV-2 antibodies. These data argue that BCG revaccination is safe and protects the elderly against COVID19. BCG revaccination may represent a viable preventive measure against COVID19.Competing Interest StatementE.J. Giamarellos-Bourboulis has received honoraria from Abbott CH, InflaRx GmbH, MSD Greece, Sobi Greece and XBiotech Inc.; independent educational grants from AbbVie, Abbott, AxisShield, bioMerieux Inc, InflaRx GmbH, Sobi and XBiotech Inc; and funding from the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grants ImmunoSep and RISKinCOVID (granted to the Hellenic Institute for the Study of Sepsis).Mihai G. Netea was supported by an ERC Advanced Grant (#833247) and a Spinoza grant of the Netherlands Organization for Scientific Research. Mihai G. Netea is a scientific founder of TTxD.The other authors do not have any competing interest to declare.Clinical TrialNCT04414267Funding StatementThe study was funded in part by the Hellenic Institute for the Study of Sepsis and in part by Fast Grants of Emergent Ventures at the Mercatus Center, George Mason University. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol and its subsequent amendments were approved by the National Ethics Committee (approval 52/20) and by the National Organization for Medicine of Greece (approval IS 045-20) (EudraCT number 2020-002448-21; Clinicaltrial.gov NCT04414267).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available upon reasonable request